KNTE insider filings

Kinnate Biopharma Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-04-05. Screen KNTE transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for KNTE between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Kinnate Biopharma Inc.

FiledFormInsiderReported transactionsSource
2024-04-054Farzan Nima — CHIEF EXECUTIVE OFFICER, DirectorDisposition to issuer (D): 2,186 · Disposition to issuer (D): 1,281,642 (derivative) · Disposition to issuer (D): 437,413 (derivative) · Disposition to issuer (D): 275,000 (derivative) · Disposition to issuer (D): 400,000 (derivative) · Disposition to issuer (D): 750,000 (derivative)EDGAR
2024-04-054Krishnamohan Neha — CHIEF FINANCIAL OFFICERDisposition to issuer (D): 64,087 · Disposition to issuer (D): 270,000 (derivative) · Disposition to issuer (D): 185,000 (derivative) · Disposition to issuer (D): 215,000 (derivative)EDGAR
2024-04-054Epperly Melissa B, — DirectorDisposition to issuer (D): 60,751 (derivative) · Disposition to issuer (D): 20,250 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 20,250 (derivative)EDGAR
2024-04-054Rome Michael E — DirectorDisposition to issuer (D): 40,501 (derivative) · Disposition to issuer (D): 20,250 (derivative)EDGAR
2024-04-054DeSimone Jill — DirectorDisposition to issuer (D): 50,000 (derivative)EDGAR
2024-04-054Meltz Mark A — COO GENERAL COUNSEL SECRETARYDisposition to issuer (D): 27,578 · Disposition to issuer (D): 384,508 (derivative) · Disposition to issuer (D): 121,503 (derivative) · Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 135,000 (derivative) · Disposition to issuer (D): 215,000 (derivative)EDGAR
2024-04-054Sabzevari Helen — DirectorDisposition to issuer (D): 40,501 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 20,250 (derivative)EDGAR
2024-04-054Foresite Capital Management IV, LLC — 10% owner
Foresite Capital Fund IV, L.P. — 10% owner
Foresite Capital Management V, LLC — 10% owner
Foresite Capital Fund V, L.P. — 10% owner
Foresite Capital Opportunity Management V, LLC — 10% owner
Foresite Capital Opportunity Fund V, L.P. — 10% owner
Disposition to issuer (D): 9,671,643 · Disposition to issuer (D): 3,525,957 · Disposition to issuer (D): 520,711EDGAR
2024-04-054Tananbaum James B. — Director, 10% ownerDisposition to issuer (D): 9,671,643 · Disposition to issuer (D): 3,525,957 · Disposition to issuer (D): 520,711 · Disposition to issuer (D): 40,501 (derivative) · Disposition to issuer (D): 20,250 (derivative)EDGAR
2024-04-054Smaldone Alsup Laurie — DirectorDisposition to issuer (D): 60,751 (derivative) · Disposition to issuer (D): 20,250 (derivative) · Disposition to issuer (D): 20,250 (derivative) · Disposition to issuer (D): 25,000 (derivative)EDGAR
2024-04-054Flaherty Keith T. — DirectorDisposition to issuer (D): 66,377 · Disposition to issuer (D): 32,064 (derivative) · Disposition to issuer (D): 56,112 (derivative) · Disposition to issuer (D): 11,391 (derivative) · Disposition to issuer (D): 20,250 (derivative) · Disposition to issuer (D): 20,250 (derivative) · +1 moreEDGAR
2024-04-054GORDON CARL L — Director, 10% ownerDisposition to issuer (D): 1,368,339 · Disposition to issuer (D): 4,738,453 · Disposition to issuer (D): 1,368,338 · Disposition to issuer (D): 84,599 · Disposition to issuer (D): 450,000 · Disposition to issuer (D): 40,501 (derivative) · +2 moreEDGAR
2024-04-054MITCHELL DEAN J — DirectorDisposition to issuer (D): 121,503 (derivative) · Disposition to issuer (D): 20,250 (derivative) · Disposition to issuer (D): 20,250 (derivative) · Disposition to issuer (D): 25,000 (derivative)EDGAR
2024-04-054ORBIMED ADVISORS LLC — Director, 10% owner
OrbiMed Capital GP VII LLC — Director, 10% owner
OrbiMed Capital GP VIII LLC — Director, 10% owner
OrbiMed Asia GP IV, L.P. — Director, 10% owner
OrbiMed Advisors IV Ltd — Director, 10% owner
OrbiMed Genesis GP LLC — Director, 10% owner
ORBIMED CAPITAL LLC — Director, 10% owner
Disposition to issuer (D): 1,368,339 · Disposition to issuer (D): 4,738,453 · Disposition to issuer (D): 1,368,338 · Disposition to issuer (D): 84,599 · Disposition to issuer (D): 450,000EDGAR
2024-03-054Krishnamohan Neha — CHIEF FINANCIAL OFFICERTax withholding (F): 1,506 @ $2.59EDGAR
2024-03-054Williams Richard Thomas — CHIEF MEDICAL OFFICERTax withholding (F): 558 @ $2.59EDGAR
2024-03-054Meltz Mark A — COO GENERAL COUNSEL SECRETARYTax withholding (F): 558 @ $2.59EDGAR
2023-12-054Williams Richard Thomas — Chief Medical OfficerTax withholding (F): 541 @ $2.25EDGAR
2023-12-054Krishnamohan Neha — Chief Financial OfficerTax withholding (F): 1,459 @ $2.25EDGAR
2023-12-054Meltz Mark A — COO General Counsel SecretaryTax withholding (F): 541 @ $2.25EDGAR
2023-09-064Krishnamohan Neha — Chief Financial OfficerTax withholding (F): 1,459 @ $2.35EDGAR
2023-09-064Williams Richard Thomas — Chief Medical OfficerTax withholding (F): 541 @ $2.35EDGAR
2023-09-064Meltz Mark A — COO General Counsel SecretaryTax withholding (F): 541 @ $2.35EDGAR
2023-06-134Epperly Melissa B, — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2023-06-134Sabzevari Helen — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2023-06-134Smaldone Alsup Laurie — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2023-06-134Flaherty Keith T. — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2023-06-134GORDON CARL L — Director, 10% ownerGrant/award (A): 25,000 (derivative) @ $0EDGAR
2023-06-134MITCHELL DEAN J — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2023-06-054Krishnamohan Neha — Chief Financial OfficerTax withholding (F): 1,459 @ $4.30EDGAR
2023-06-054Williams Richard Thomas — Chief Medical OfficerTax withholding (F): 541 @ $4.30EDGAR
2023-06-054Meltz Mark A — COO General Counsel SecretaryTax withholding (F): 541 @ $4.30EDGAR
2023-05-104Foresite Capital Management IV, LLC — 10% owner
Foresite Capital Fund IV, L.P. — 10% owner
Foresite Capital Fund V, L.P. — 10% owner
Foresite Capital Management V, LLC — 10% owner
Foresite Capital Opportunity Fund V, L.P. — 10% owner
Foresite Capital Opportunity Management V, LLC — 10% owner
Purchase (P): 1,550,956 @ $2.80 · Purchase (P): 229,044 @ $2.80EDGAR
2023-05-104Tananbaum James B. — Director, 10% ownerPurchase (P): 1,550,956 @ $2.80 · Purchase (P): 229,044 @ $2.80EDGAR
2023-05-084GORDON CARL L — Director, 10% ownerPurchase (P): 83,459 @ $2.75 · Purchase (P): 312,991 @ $2.75 · Purchase (P): 83,459 @ $2.75 · Purchase (P): 490,512 @ $2.82 · Purchase (P): 490,511 @ $2.82EDGAR
2023-05-084ORBIMED ADVISORS LLC — Director, 10% owner
OrbiMed Capital GP VII LLC — Director, 10% owner
OrbiMed Capital GP VIII LLC — Director, 10% owner
OrbiMed Asia GP IV, L.P. — Director, 10% owner
OrbiMed Advisors IV Ltd — Director, 10% owner
OrbiMed Genesis GP LLC — Director, 10% owner
ORBIMED CAPITAL LLC — Director, 10% owner
Purchase (P): 83,459 @ $2.75 · Purchase (P): 312,991 @ $2.75 · Purchase (P): 83,459 @ $2.75 · Purchase (P): 490,512 @ $2.82 · Purchase (P): 490,511 @ $2.82EDGAR
2023-05-024GORDON CARL L — Director, 10% ownerPurchase (P): 60,998 @ $2.55 · Purchase (P): 228,754 @ $2.55 · Purchase (P): 60,997 @ $2.55 · Purchase (P): 124,544 @ $2.62 · Purchase (P): 467,068 @ $2.62 · Purchase (P): 124,545 @ $2.62 · +3 moreEDGAR
2023-05-024ORBIMED ADVISORS LLC — Director, 10% owner
OrbiMed Capital GP VII LLC — Director, 10% owner
OrbiMed Capital GP VIII LLC — Director, 10% owner
OrbiMed Asia GP IV, L.P. — Director, 10% owner
OrbiMed Advisors IV Ltd — Director, 10% owner
OrbiMed Genesis GP LLC — Director, 10% owner
ORBIMED CAPITAL LLC — Director, 10% owner
Purchase (P): 60,998 @ $2.55 · Purchase (P): 228,754 @ $2.55 · Purchase (P): 60,997 @ $2.55 · Purchase (P): 124,544 @ $2.62 · Purchase (P): 467,068 @ $2.62 · Purchase (P): 124,545 @ $2.62 · +3 moreEDGAR
2023-03-034Williams Richard Thomas — Chief Medical OfficerTax withholding (F): 638 @ $5.21EDGAR
2023-03-034Krishnamohan Neha — Chief Financial OfficerTax withholding (F): 1,721 @ $5.21EDGAR
2023-03-034DeSimone Jill — DirectorGrant/award (A): 50,000 (derivative) @ $0EDGAR
2023-03-034Meltz Mark A — COO General Counsel SecretaryTax withholding (F): 638 @ $5.21EDGAR
2023-02-234ORBIMED ADVISORS LLC — Director, 10% owner
OrbiMed Capital GP VII LLC — Director, 10% owner
OrbiMed Capital GP VIII LLC — Director, 10% owner
OrbiMed Asia GP IV, L.P. — Director, 10% owner
OrbiMed Advisors IV Ltd — Director, 10% owner
OrbiMed Genesis GP LLC — Director, 10% owner
ORBIMED CAPITAL LLC — Director, 10% owner
Grant/award (A): 550,000 · Grant/award (A): 550,000EDGAR
2023-02-224Foresite Capital Management IV, LLC — 10% owner
Foresite Capital Fund IV, L.P. — 10% owner
Foresite Capital Fund V, L.P. — 10% owner
Foresite Capital Management V, LLC — 10% owner
Foresite Capital Opportunity Fund V, L.P. — 10% owner
Foresite Capital Opportunity Management V, LLC — 10% owner
Other (J): 1,100,000EDGAR
2023-02-224Tananbaum James B. — Director, 10% ownerOther (J): 1,100,000EDGAR
2023-02-224GORDON CARL L — Director, 10% ownerGrant/award (A): 550,000 · Grant/award (A): 550,000EDGAR
2023-02-154/AFarzan Nima — Chief Executive Officer, DirectorGrant/award (A): 750,000 (derivative) @ $0EDGAR
2023-02-144Williams Richard Thomas — Chief Medical OfficerGrant/award (A): 215,000 (derivative) @ $0EDGAR
2023-02-144Farzan Nima — Chief Executive Officer, DirectorGrant/award (A): 750,000 (derivative) @ $0EDGAR
2023-02-144Meltz Mark A — COO General Counsel SecretaryGrant/award (A): 215,000 (derivative) @ $0EDGAR

Recent 8-K events — Kinnate Biopharma Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2024-04-038-K2.01 — Completion of Acquisition or Disposition of Assets
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2024-03-018-K1.01 — Entry into a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2024-02-168-K1.01 — Entry into a Material Definitive Agreement
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2024-01-168-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2023-11-228-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2023-11-158-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2023-11-098-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2023-09-188-K2.02 — Results of Operations and Financial Condition
?
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2023-08-088-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2023-07-288-K5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=KNTE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs